>PROKKA_00001 Clostridium P-47 protein
MNNLKPFIYYDWEKTILKNTKENYSINEIIPKTFFMELHGTKITNSTLNGTWKSWNLTNE
GEGSYPVLKCIIDDGYLDMNFGASSEKIPLKNVWIKLCMKINPNSDGTYSIPEKSSSFYI
KDNSLKISKDNLILDKYLNKLMLSYFKNNIKNIEMFINKSRIQTKVVGDLSLLGWNTENS
VSFRTMNEFIKKDNLYPKDFKAVYSYRKMTFTATGTFDSWEMTTGADGRNIRFKCPIKYA
VYDLDGDVFNSSTENFLLIQVDLTYFDSKTTINDPTGENDGKQFNLKIKTNDDKLKNVLI
VTYNLTDTDGSMSSEDKDFLSLAFRNWFNENIQQFEQIFAYILLDETAKIPEYQWLKPTQ
ISYGSASVETANDEPDLDASIFSAMSMVENNTNSTPSHAVDNRMLQLTKTQAAFGISFPL
FIEHFLKQALLSSQFISVDDIVADINTLTITNNKQIIFGKVENSDGKNVDSSLKPGKLKL
SLQNNLIVLELFDLTWEQGRGVTGHFDFRQEYELALESKSGKQIPILKVHDEPEIEYYVE
EAQWKTNEDMIVSAVVGTVFSMILGASMKLAGSALSKAGKLIRSKATTIKGRKKIYINRS
NVRQLRKDSGATEIELERINRRNSSIAAEDARLISNNGTTSIQTLGDMKKKPMSTGQRIA
IGAKKIAGTAVMFGAVGLGMNFGEMLINYINAMENNDYSAIPGINSFMQQCIGAMQWPDK
DSELKVTFGKLQGIYLLGGTLEKNNKTDNK*
>PROKKA_00002 hypothetical protein
MKQTFPFNFDDALLNTGGSIHLEKVNQNCSPNYQYFKIKFIEGYLHIKNKSGDILEKYDL
KDLISLIALKKDYLKLSPLNNKKPKEFTNIKNKHLENRFNLYVINEDINGKITKNGILEE
IILNRLLLSIFLENEENLLQIA*
>PROKKA_00003 RNA polymerase factor sigma-70
MKNLFFLMNTLKDDNEKFKKIYMNYKDLIDIFTTKYNLSENYNDILNHFWIILKKADLNK
FNTEDDLNKYISKCLKRYCLSICMKKNRDKKIIYNSEITDINLNLIQDNCFNDIEFEFKD
LISILPNTQKNIIYMKFFKDMKDIEIAKKLKISRQSVYKNKNLALEKLKPILKELINI*
>PROKKA_00004 Clostridium P-47 protein
MNTYGWDIVYGCSKRVVNKHLKEYITKNNIQFLYSNIDKKQEIKMVFDNWEIINGGSSNF
LRIKTPIKEGYFKVRNTTVDLSGINPVLEIKLDFFNDISNPNIKELKFNFGSESNDDIKI
IVSDLNGNLQEEDEFYFNKLLINAFIQNEKQISYIFASLNVTSDIEWMNPKQFKFVYYSP
TDNSDGYLFILSVVTNRDISKLSANVDGNILGNNSEVGLLISEKLFLQNMVLSRLSSNMG
SNINKNNFEVISTSDTTGRIVNNSTLNWYGLKVAALYYYPKINNFSMQLFEGNKLKISLR
GLVRLTGLEAVYSDFEIQSINKFVYNSTNKKAYFEVDKNPTSSYKYHLFPGDLISLAVLS
SVTHWSIKSIEGALGFELINNFVDLINNTIKWNNLKISQVTNVTLNVGFCIQGNAN*
>PROKKA_00005 Botulinum neurotoxin type E precursor
MKINNNFNIDSLIDNRDVAIVRGRKTDTFFKVFQVAPNIWVAPERYYGESLNINEDQKSD
GGIYDSNFLLTNDEKDEFLQATVKILQRINNNVIGAKLLSLISTAIPFPYEYKPGDYRQT
NYLVSKDNQHYYTANLVIFGPGTNIVENNAVYYKKEDSENGMGTMSEIWFQPFLTYKYDQ
FYVDPALELIKCLIKSLYYLYGIKPSDDLSIPYRLRSEFNSLEYSELDMVDFLISGGTDY
KLLNTNPYWFTDNYFINAPKNFEKYKNDYETKIKNNNDIANSIKLYLEQKFKTNVQDIWE
LNLSYFSTEFEIMMPEIFNNALNHYHRKEYYVIDYFKNYNINGFINGQIKTILLLSKYNK
NIINKPELIVNLINENNSVLMKSNIYGDGLKGTIGNFYAVYKIPYNIGDEYHINSSDSCL
DNVDIKEIDNIPPINDADIYPYRKNCDPFTPVYNITETKEINTTIPFPVNYLQAQVTNSN
DINLSSDFLKVISSKDRSLVYSFLDNTIDYLDSIKYDGPIDTDKKYYLWLKEIFRNYSFD
MTETQEVNTLCGFNKVVPWLGKALNILNTGNSFIEEFKTLGPISLINKKENITMPKIEID
EIPNSMLNLSFKDLSENLFNIFSKNNSYFEKIYYDFLDQWWTQYYSQYFDLICMAKRSVL
AQESLIKKIIQKKLSYLIGNSNISSDNLALMNLTTTNTLRDISNESQIAMNNVNNFLNNV
AICVFQTNIYPKFISFMEQCINNINKNTREFIQKCTNITENEKLQLINQNIFSSLDFDFL
NIENLKSLFNSETGLLIKEETSPYELVLYAFQEPGNNAIGDASGKNTSIEYSKDIGLVYG
INSDALYLNGSNQSISFSNDFFENGLTNSFSIYFWLRNLGKDTIKSKLIGSKEDNCGWEI
YFQDTGLVFNMIDSNGNEKNIYLSDVSNNSWHYITISVDRLKEQLLIFIDDNLVANESIK
EILNIYSSNIISLLSENNPSYIEGLTILNKPTTSQEVLSNYFKVLNNSYIRDSSEERLEY
NKTYQLYNYVFSENPIYEIKQNNNIYLTINNTNNLNLQVSKFKLLSINPNKQYVQKLDEV
IISVLDNMEKYIDISEDNRLQLIDNKNNAKKMIISNDIFISNCLTLSYNGKYICLSMKDE
NHNWMICNNDMSKYLYLWSFK*
>PROKKA_00006 Botulinum neurotoxin type A precursor
MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN
PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG
STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY
GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN
RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA
KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV
LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT
GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE
ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG
KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA
AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG
AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK
VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA
MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK
VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI
GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN
EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT
NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN
EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYIDVNNVGIRGYMYLKGPR
GNVMTTNIYLNSSLYMGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA
GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK
LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL*
>PROKKA_00007 hypothetical protein
MLISSYFNLFNIITVRKNTIFIVNTSLVVYLINDTRYHYNDFANYSFE*
>PROKKA_00008 hypothetical protein
VQIDLYEAMKSCYIPKYKELMEEVSPNDHKFEDIIKRTKDFYIERML*
>PROKKA_00009 Autolytic lysozyme
MLKGIDVSEHQGEIGWKAVKNSGIQFAILRAGYGKNNIDKQFINNANGCTSVGMPFGLYW
FSYAYTENMARKEAQYCVAQAKKYKISYPICYDLEYDTIRYANNCGVTITKSLATKMVHA
FCQEVERNGYFAMNYSNQDFLLNKFDSNLLKRYALWYAWYNNSLNRTCGIWQYSENGRVP
GIAGAAVDMNYCYLNMPGASNTSPNKNAFRGGHYLIRELQKEINSQGLGEVVVDGIAGQA
TINSAPICKQGARGGITKVIQQMLISIGYPVGSHGVDGVFGDSTVTAIKAFQRDCHLVAD
GIVGKETWKALFRNLK*
>PROKKA_00010 hypothetical protein
MKTIRFKIVAGINEGYFHENENKNRIQIVGV*
>PROKKA_00011 Nucleoside 2-deoxyribosyltransferase
MNKRVFLAAPFKGAIKEKQSIMKEQEKKRIENLILFLEEKGWEVDNAHRREEWGANFMSP
DQCTKLDYDAIKECDLFIAFPGVPVSPGTHIEIGWASAMDKEIILLLAEKEENYAYLIRG
LHTVSNVHYIIYNEEKEYLQKLDLYLDGENNEV*
>PROKKA_00012 Thymidylate synthase
MKFKNFHEAYLRNLNDVYYNPEFINQPRGNVSKERLNYFMILENPRERICYTKSRKTNIV
FNFAEALWYLSGSNDLDYISYYASNMKKYSMDGKTLTGTAYGPKIFSYGYNKINQWHRIV
ELFKEDQDTKRGFIEIFDANEDLSLKNIDVSCTIGFQFFIRKHKLYMTTFMRANDAYRGI
ISDVFSFTFIQEFLATELNLDIGQYSHQVATTHIYEPDFKLAEKVLCESKSVKKELSFPR
MPKKDNWEDLKIVLQYEKELRKQSIHLTKKDIDELEIDKYWKQIICLFVLYQEIYYGDNL
DYEIYESLEPLYQYLFSNKWNQYF*
>PROKKA_00013 ubiquinone/menaquinone biosynthesis methyltransferase
MESIFLGGNILGTCWKDEGVSKKFNLYNDMLENILGFNYIFENLKSNESIKKILDFGCGP
GKVAERMAKIKPESQIIAVDQSQNMLDIAMKEHNKENIDYKLIEQNQLKEIEKNSIDCVV
LCFVIINNSDKDRIKTIFQEIFRVLKKGGKFFILDSNPNAAGVEFSTFTNGKSGQAYHLG
DHKKQFLKIPNNEVLILEDYYWPIDFYINNLEAVGFENYKIVEPTIEKINKPDLNAIEKT
YDIECWGSEKNKPPFIIFDVEK*
>PROKKA_00014 Thiaminase-1 precursor
MKLKNLFKRSLSLLFSFIMIFTLVSGLNVKAFSGDEPKQTLNVALYEYVPDPIRFKKAVE
TEWNKKEPNIKLNFVDWDCYSEDPPKDLDVFVFDAIYLSHFVKEGYLSEIPEKDIKNKED
ILPFAMEGCTIKGSAYAIPQIICTNLLFSRKGDSDIQNINSVFDLNDKLGKNTSEDIIPP
ENKGLLIDMSGGTSKACMYLDSLIDTTQEYTKFCSLPNLNELNKDAIESLVLLQSMAGKS
QANYWPENNDSYIRAKWFINGKGRAYIGYTEAMSQMKEFANDIDFKTISLSKNSNIPIFY
GDVVGINSSITNSYKKEKAIELANIITDKNTMVNAVSPDENNKYPQYLLPARRSVYHNLE
NKYPIYGKLYKIADNSNNKLFRTGPEIREWLKQAKKIITEYLQQ*
>PROKKA_00015 Hydroxymethylpyrimidine/phosphomethylpyrimidine kinase
MKKVLSIAGSDCSGGAGIQADLKTFSAHGVFGMSVIVSVVAENTSRVIDIQDVTPDMIKS
QIDAVYEDIGTDAVKIGMLSTPDCMKAVSEKLQEYKPKNVVIDPVMYAKNGCPLMDPNSV
STLIQSIIYHADILTPNIPEAERISGYKIKTLEDMEKAAGIIEGMGCKSVLIKGGHYIGD
AVDVLYDGNKFYHYKTQRIHTKNTHGTGCTLSSAIASNLALGFEINEAVKRAKNYITMAI
EHSLEIGKGNGPTNHFYQVYLNGLKGMELDNHTRS*
>PROKKA_00016 hypothetical protein
MRKVYKNPKELATCLKDLVDLYFEDLMTYEKLEEKVSKIIEANKDSIYKNGVINTKLANV
LGDLRIDVINKIVKEK*
>PROKKA_00017 putative membrane protein
MTKYAIVFFMSMVPIVELRGAIPYSQIYNLPLLQSFIVAIIGNMLPMPFIYLFARKVLVW
GADKPITGKFFTWCLEKGEKAGKKLQEKTGKKGLFWGLLIFVAIPAPGTGAWTGTLAASL
LDMDFKTSILAVMLGVLVAGIIMGTASVGLFSFF*
>PROKKA_00018 putative ABC transporter ATP-binding protein YxlF
MDKPNDVVVSIRNLKMSYGSKEVLKGINLDVNKGEIIGYIGPNGAGKSTTVKIMLGLVKG
YEGEVKIFGNNISYENVEYKHKIGYVPENGEIYDNLTAYEYITFLGEIYGMELKEVNNKA
KKLMSLFGIKEAYHSRISSYSKGMRQKLLIISSLIHNPDILFLDEPLSGLDANSVLVFKE
VLSKLASEGKTIFYSSHIMEVVEKISSRIILLNNGQIGADGTFEELKKKNMEGSLEQIFN
QITGFTKHEEIANEFISILKEV*
>PROKKA_00019 hypothetical protein
MIKNIMAPIFILIFTIIGDGIKIKTARKTPINPYRNSDFLKVFFLFSFSLSLYIVGTLLL
SIKSFNLSIVLMEA*
